Predicting outcomes after heated chemotherapy for stomach or colon spread
Part of Cancer, Digestive system clinical trials.
This study tries to better predict how well patients do after heated chemotherapy placed in the abdomen during surgery for stomach or colon cancer that has spread to the lining of the abdomen. It may help doctors choose the best treatment plan and timing for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach, gastroesophageal junction, colon, or rectal cancer with spread on the abdominal lining (peritoneal metastasis).
- During surgery, doctors must confirm the cancer is on the abdominal lining using tissue samples (biopsy/histology).
- Your tumor spread in the abdomen must be limited (PCI ≤ 15 for stomach; ≤ 20 for colon/rectum).
- The surgeon must be able to remove the abdominal lining cancer completely or almost completely (CCS 0–1) with a curative-intent operation.
- You must be well enough for surgery and heated chemotherapy (HIPEC), with no major heart problems or other surgery/HIPEC blockers.
- You must not have cancer spread to organs that can’t be removed (non-resectable distant metastases), and you must not be planning pregnancy during the treatment window.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares standard laparoscopic surgery for stomach cancer versus the same surgery plus HIPEC, which is heated chemotherapy placed in the abdomen during the operation. It aims to see if adding the heated chemotherapy improves outcomes for people with higher-stage stomach cancer.
This trial tests if adding heated chemotherapy (HIPEC) right after stomach cancer surgery can help people with locally advanced gastric cancer live longer. It's for patients whose cancer has not spread to other parts of the body and who are fit enough for major surgery.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This Phase 3 trial studies whether adding a heated chemotherapy procedure during surgery (HIPEC) before the main cancer treatment can lower the chance that stomach cancer returns in the belly. It is for people with advanced stomach cancer who are at higher risk of cancer coming back in the peritoneum (the lining of the abdomen).
This study looks at adding a heated medicine treatment (HIPEC with mitomycin C) during surgery to treat colon cancer that has spread to the lining of the abdomen (peritoneum). It aims to improve outcomes after surgeons remove visible tumor completely.
This Phase 1 trial tests a treatment that delivers heated chemotherapy directly into the abdomen (HIPEC) for certain cancers that have spread only within the abdominal lining. It aims to see how safely and effectively this approach works, especially when doctors can remove as much tumor as possible.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.